Literature DB >> 16157427

Imprinting of BALB/c mice with low Leishmania infantum parasite dose markedly protects spleen against high-dose challenge.

Bernard Ferrua1, Carmelo Luci, Yves Le Fichoux, Audrey Paul, Pierre Marty.   

Abstract

In this study, we investigated in the BALB/c model, the dose-dependent protective potential of previous infection with Leishmania infantum parasites, against a high-dose challenge and showed for the first time that low-dose imprinting conferred substantial spleen resistance. Mice were immunized for 1 month or 5 months by IV route with parasite inocula ranging from 10(4) to 10(7) and from 10(3) to 10(5), respectively, and challenged for 1 month with 3 x 10(7) parasites. Liver protection was directly proportional to the parasite dose used for infection and reached 90-95% whereas, only low doses (< or =10(5)) protected spleen. Maximal spleen resistance (80%) was reached in mice infected for 5 months with 10(5) parasites. In most cases, protection was accompanied in spleen, by restored in vitro responses to Leishmania antigens. Analysis of anti L. infantum isotype responses and in vitro antigen-induced cytokine production, indicated that the acquired protection was irrespective of a Th1/Th2 imbalance.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16157427     DOI: 10.1016/j.vaccine.2005.08.057

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  4 in total

1.  Antigenemia in patients with mediterranean visceral leishmaniasis.

Authors:  Bernard Ferrua; Nicolas Rol; Grégory Michel; Pierre Marty
Journal:  J Clin Microbiol       Date:  2009-09-16       Impact factor: 5.948

2.  Luciferase-expressing Leishmania infantum allows the monitoring of amastigote population size, in vivo, ex vivo and in vitro.

Authors:  Grégory Michel; Bernard Ferrua; Thierry Lang; Madhavi P Maddugoda; Patrick Munro; Christelle Pomares; Emmanuel Lemichez; Pierre Marty
Journal:  PLoS Negl Trop Dis       Date:  2011-09-13

3.  Evaluation of the protection conferred by a naturally attenuated Neospora caninum isolate against congenital and cerebral neosporosis in mice.

Authors:  Silvia Rojo-Montejo; Esther Collantes-Fernández; Inmaculada López-Pérez; Verónica Risco-Castillo; Antoni Prenafeta; Luis Miguel Ortega-Mora
Journal:  Vet Res       Date:  2012-08-22       Impact factor: 3.683

4.  Immunoadjuvant Properties of the Rho Activating Factor CNF1 in Prophylactic and Curative Vaccination against Leishmania infantum.

Authors:  Grégory Michel; Bernard Ferrua; Patrick Munro; Laurent Boyer; Nassim Mathal; Daniel Gillet; Pierre Marty; Emmanuel Lemichez
Journal:  PLoS One       Date:  2016-06-03       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.